The outcome of gynecologic cancer patients with Covid-19 infection: A systematic review and meta-analysis [version 1; peer review: awaiting peer review]

I Gde Sastra Winata\textsuperscript{1}, Januar Simatupang\textsuperscript{2}, Arie A Polim\textsuperscript{3,4}, Yakob Togar\textsuperscript{2}, Advenny Elisabeth Tondang\textsuperscript{2}

\textsuperscript{1}Gynecology & Oncology, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia
\textsuperscript{2}Obstetric & Gynecology, Faculty of Medicine, Christian University of Indonesia, Jakarta, Indonesia
\textsuperscript{3}Reproductive Endocrinology and Infertility, School of Medicine and Health Sciences, Atmajaya Catholic University of Indonesia, Jakarta, Indonesia
\textsuperscript{4}Reproductive Endocrinology and Infertility, Morula IVF, Jakarta, Indonesia

Abstract

\textbf{Background:} Cancer is a comorbidity that leads to progressive worsening of coronavirus disease 2019 (Covid-19) with increased mortality. This is a systematic review and meta-analysis to yield evidence of adverse outcomes of Covid-19 in gynecologic cancer.

\textbf{Methods:} Searches through PubMed, Google Scholar, ScienceDirect, and medRxiv to find articles on the outcome of gynecologic cancer with Covid-19 (24 July 2021–19 February 2022). The Newcastle-Ottawa Scale tool was used to evaluate the quality of included studies. Pooled odds ratio (OR), 95% confidence interval (CI) and random-effects model were presented.

\textbf{Results:} We accepted 51 studies (a total of 1991 gynecologic cancer patients with Covid-19). Covid-19 infection cases were lower in gynecologic cancer vs hematologic cancer (OR 0.71, CI 0.56-0.90, \textit{p} 0.005). Severe Covid-19 infection and death were lower in gynecologic cancer vs lung and hematologic cancer (OR 0.36, CI 0.16-0.80, \textit{p} 0.01), (OR 0.52, CI 0.44-0.62, \textit{p} <0.0001), (OR 0.26, CI 0.10-0.67 \textit{p} 0.005), (OR 0.63, CI 0.47-0.83, \textit{p} 0.001) respectively. Increased Covid death was seen in gynecologic cancer vs population with breast cancer, non-Covid cancer, and non-cancer Covid (OR 1.50, CI 1.20-1.88, \textit{p} 0.0004), (OR 11.83, CI 8.20-17.07, \textit{p} <0.0001), (OR 2.98, CI 2.23-3.98, \textit{p} <0.0001) respectively.

\textbf{Conclusion:} Gynecologic cancer has higher Covid-19 adverse outcomes compared to non-cancer, breast cancer, non-metastatic, and Covid-19 negative population. Gynecologic cancer has fewer
Covid-19 adverse outcomes compared to other cancer types, lung cancer, and hematologic cancer. These findings may aid health policies and services during the ongoing global pandemic.

**PROSPERO Registration:** CRD42021256557 (22/05/21)

**Keywords**
COVID-19, Critical care outcome, Female genital neoplasms, Hospitalization, Morbidity, Mortality

This article is included in the Emerging Diseases and Outbreaks gateway.

This article is included in the Coronavirus collection.

**Corresponding author:** Yakob Togar (vincentharlingcute@gmail.com)

**Author roles:** Winata IGS: Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Simatupang J: Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization; Polim AA: Conceptualization, Investigation, Methodology, Supervision, Validation, Visualization; Togar Y: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Software, Writing – Original Draft Preparation, Writing – Review & Editing; Tondang AE: Data Curation, Investigation, Methodology, Project Administration, Resources, Software

**Competing interests:** No competing interests were disclosed.

**Grant information:** The author(s) declared that no grants were involved in supporting this work.

**Copyright:** © 2022 Winata IGS et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Winata IGS, Simatupang J, Polim AA et al. The outcome of gynecologic cancer patients with Covid-19 infection: A systematic review and meta-analysis [version 1; peer review: awaiting peer review] F1000Research 2022, 11:525 https://doi.org/10.12688/f1000research.111349.1

**First published:** 16 May 2022, 11:525 https://doi.org/10.12688/f1000research.111349.1
Introduction
The Covid-19 pandemic has changed the way health care providers around the world manage care provided to their patients. The pandemic has also proven to shift the attitude of standard practice and procedure between providers and patients, for example, to reduce gynecologic cancer patients visiting the hospital as possible because the risk of getting infected with Covid-19 is increased regarding their comorbidities.1 Despite this circumstance, gynecologic cancer patients are still often required to perform routine hospital visits for treatments or other medical procedures under guidance made by gynecological cancer societies during the Covid-19 pandemic.2 The cancer incidence and mortality are still increasing around the world. According to Global Cancer Statistic: 2020 for gynecologic cancer, there are 604,127, 417,367, 313,959, 45,240, and 17,908 new cases of cancer of the cervix uteri, corpus uteri, ovary, vulva, and vagina respectively. 3 Most concerns are coming from these patients about how they may proceed to seek or continue their cancer treatment and surveillance during the Covid-19 pandemic.4 Studies are showing various results on increased mortality and severity among cancer patients infected with Covid-19. Systematic review and meta-analysis studying the outcome of cancer patients with Covid-19 show 2.1–4% proportion of cancer patients among those infected with Covid-19, additionally compared to non-cancer with Covid-19 greater amount of mortality and severity are observed in cancer population with Covid-19.5–7 However studies and data on the outcome of gynecologic cancer patients with Covid-19 are still lacking. Several SARS-CoV-2 variants of concern listed by WHO (World Health Organization) pose challenges in mitigating the pandemic as these variants often increase transmission rate and severity.8 The world has been experiencing a wave of active case surges by these variants and on 26 November 2021 the WHO designated the variant Omicron (B.1.1.529) as an addition to the list.9 Thus we attempt to review the literature and quantify the effect of the SARS-CoV-2/ Covid-19 infection among gynecologic cancer patients to assess whether the risk of infection, hospitalization, severity, and mortality are increased than non-gynecologic cancer population.

Methods
We conducted this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses/PRISMA statement.10,82 This study and its protocol were registered to PROSPERO (CRD42021256557).

Eligibility criteria
We took into consideration of studies with observational cohort studies, case-control, cross-sectional, case report, and case series designs that evaluate the outcome of gynecologic cancer patients infected with Covid-19 from the year 2019. Each study ought to report Covid-19 associated infection, hospital admission, mortality, severity, or admission to the intensive care unit (ICU); a summary of eligible studies and its extracted outcome of interest were managed in the Microsoft Excel spreadsheet provided in the Underlying data.82 We exclude studies other than the English language, reviews or guidelines, and inconceivable results of the sought outcome.

Comparator(s)/control
Non-cancer Covid-19 patients, non-Covid-19 cancer patients, other cancer types/non-gynecological cancer with Covid-19.

Database and literature search
Study articles were systematically searched through PubMed/Medline, ScienceDirect, Google Scholar, and medRxiv. Relevant articles had been screened from 24 July 2021 to 19 February 2022. Reference searches from retrieved articles citation lists were identified if any were needed. Boolean operators technique used for Pubmed/Medline search with (“COVID-19” or “2019-nCoV” or “SARS-CoV” or SARS-CoV2 or 2019-nCov or “2019 coronavirus” or covid19) AND (gynecology or gynaecology) AND (tumor or malignancy or cancer) AND (outcomes or outcome) AND (gyn* tum* or gyn *malign* or gyn* cancer) AND (cancer surgery or oncolog* surger*) AND (brachytherapy or radiotherapy). We used “Gynecologic cancer AND Covid-19” with Google Scholar, Science Direct, and medRxiv. Two authors separately handled the literature search. Findings were accumulated and stored in Mendeley and Zotero for management and automated duplicate identification. Thorough stepwise screening from title and abstract was then conducted to determine possible article inclusion. Potentially eligible studies were then evaluated for in-depth full-text review. Each author would consult senior authors to resolve any differences found during the literature’s selection process.

Data extraction and quality assessment
The data was extracted independently by two authors and stored them in the Microsoft Excel spreadsheet. Data was then discussed for an agreement. Name of authors, year of publication, country, type of studies, study period, number of patients, comparators, and target conditions was collected. The NOS/Newcastle-Ottawa Scale was used by authors to assess the quality of the cohort and case-control study, and The Joanna Briggs Institute (JBI) Critical Appraisal Checklist for an analytical cross-sectional study.11 The assessment was performed by two authors and the results were discussed with the first author.
**Meta-analysis outcome**

The main outcome of interest was Covid-19 mortality and severity. Covid-19 severity is defined as either ICU admission, acute respiratory distress syndrome (ARDS), or need for mechanical ventilation. Covid-19 infection and hospitalization were decided as secondary outcomes.

**Data analysis & synthesis**

We performed data analysis mainly using Review Manager 5.4.1 (RevMan 5.4.1) by Cochrane collaboration.12 If needed, additional synthesis was then performed with STATA-16. We synthesized the dichotomous outcome from each study with an odds ratio (OR). The random-effects model (DerSimonian and Laird) was used to present pooled OR with 95% CI (confidence interval) and the result of overall effect (p). We addressed the presence of heterogeneity with I^2 as 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity according to the Cochrane Handbook for Systematic Reviews of Interventions. We performed subgroup analysis by age, gender, other comorbidities status, cancer type, cancer stage, presence of metastatic disease, and active cancer treatment. Sensitivity analysis was performed by dividing multi-center/ single-center studies and removing/including the latest study period if concerns were raised of patients population duplication thus we could present robust pooled evidence.13

**Results**

All supplementary files can be found in the Extended data.82

A total of 51 studies involving the Covid-19 positive population were identified; among them were 1991 gynecologic cancer patients, 221465 non-cancer patients, and 28138 other cancer type patients. In total, 3,717,078 cancer patients were found to be Covid-19 free. Study selection and summary of included studies were presented in Figure 1 and Table 1. The risk of bias in each study was shown in Figures S1 and S2. Due to high heterogeneity found in adverse Covid-19 outcomes (Covid-19 death \( I^2 82\% \)), (Covid-19 hospitalization \( I^2 92\% \)), (Covid-19 infection case \( I^2 72\% \)), we decided to perform subgroup analysis.

![Figure 1. Study flow diagram.](image-url)
| Author          | Location       | Type of study                  | Time of study          | Publication year | Non-cancer Covid patients | Gynecology Oncology Covid patients | Other Oncology Covid patients | Cancer non Covid patients | Gender | Gender stage | Comorbidities | Cancer treatment | Age | Outcome                      |
|-----------------|----------------|-------------------------------|------------------------|------------------|--------------------------|-----------------------------------|---------------------------------|----------------------------|--------|---------------|----------------|----------------|------|-----------------------------|
| Angelis V et al. | United Kingdom | Multi center, prospective cohort | March-April 2020       | 2020             | NA                       | 6                                 | 107 (Lung 15, Breast 18, Hematological 18) | 13376 (Gynecological 967) | Male63, Female50 | NA            | Hypertension 39, Diabetes 18, Ischemic heart disease 13, COPD 6 | SACT 85, Radiotherapy 11 | Median 66, IQR: 54–69, range 21–91 | Covid infection & Covid death |
| Ayhan A et al.   | Turkey         | Multi center, prospective cohort | March-April 2020       | 2020             | NA                       | 46                                | 642 (Gynecological)               | Female688                   | NA            | Hypertension 29, Diabetes 16, Chronic pulmonary disease 11, Coronary heart disease 6, CKD 1 | Major/Complex Cancer Surgery 688 | <65: 34, >65: 12 | Covid death |
| Ayhan M et al.   | Turkey         | Single center, retrospective cohort | March-June 2021       | 2021             | NA                       | 4 (Ovarian 1, Endometrium 3)     | 80 (Lung 27, Breast 18)            | Female33, Male51              | 1, 2, 7, 11, 13, Metastasis 57, Non-metastasis 27 | Hypertension 12, Diabetes 16, Coronary artery disease 3, COPD 3, CKD 1 | SACT 84 | Median 61, IQR: 21–84 | Covid infection & Covid hospitalization |
| Ayhan M et al.   | Turkey         | Single center, retrospective cohort | March-May 2021        | 2021             | 2289                     | 7 (Cervix 3, Endometrial 2, Ovarian 2) | 85 (Lung 26, Breast 17)           | Female41, Male51 | Metastasis 53, Non-metastasis 39 | Hypertension 31, Diabetes 16, COPD 14, Coronary artery disease 13, CKD 4, Chronic liver disease 2, Cerebrovascular disease 2 | SACT 62 | <67: 45, >67: 47 | Covid death |
| Basse C et al.   | France         | Single center, prospective cohort | March 2020            | 2020             | NA                       | 12                               | 129 (Lung 18, Breast 57, Hematological 19) | Female102, Male39 | NA            | Hypertension 15, Diabetes 24, Hypertension 48, Other heart disease 21, Systemic disease 6 | Surgery 11, Radiotherapy 13, SACT 120, None 17 | >70: 141 | Covid death |
| Bernard A et al. | France         | Multi center, prospective cohort | March-April 2020       | 2021             | 83329                    | 185                              | 5537 (Lung 873, Breast 561, Hematological 1389) | Female39919, Male45079 | Metastasis 1775, Non-metastasis 2558 | Hypertension 28163, Heart failure 6641, Chronic respiratory disease 1334, COPD 6948, Diabetes 1626, COPD 4516, Obesity 8289, Crohn 673 | NA | With cancer: mean 72, Without cancer: mean 65 | Covid death |
| Bersanelli M et al. | Italy       | Multi center, prospective cohort | January-April 2020       | 2020             | NA                       | 1 (Endometrial)                  | 13 (Lung 9, Breast 1)              | Female3, Male10 | N: 9 | Splenectomy 1, Hypertension 8, HIV 1, Diabetes 1 | IC13, IC13 + Chemotherapy 1 | <65: 5, >65: 9 | Covid death |
| Bogni G et al.   | Italy          | Single center, retrospective cohort | February-March 2020   | 2020             | NA                       | 190(Ovarian 14, Endometrial 3, Cervical 1, Ovarian + Endometrial 1) | NA | Female19 | NA | Cardiomyosaromal disease 5, COPD 1, Hypothyroidism 2, Plummer disease 1 | Surgery 5, SACT 8, Planned treatment 6 | <65: 9, >65: 10 | Covid death |
| Cavanna L et al. | Italy         | Single center, retrospective cohort | April–June 2020       | 2021             | NA                       | 0                                | 10 (Lung 2)                        | Female2, Male8 | NA            | SACT 7, Hormonal 1 | Mean 69.2, Range 54–80 | Covid infection |
| Chai C et al.    | China          | Multi center, prospective cohort | January-March 2020  | Pre-prints       | 498                      | 16 (Gynecological 9, Ovarian 4, Endometrial 3) | 150 (Lung 25, Breast 19, Hematological 17) | Female336, Male328 | NA            | Hypertension 226, Diabetes 128, Hyperlipidemia 109, Heart disease 79, Cerebrovascular disease 22, COPD 36, CKD 14, Chronic liver disease 12 | NA | Median 65, IQR 59–70 | Covid infection |
Table 1. Continued

| Author                 | Location       | Type of study               | Time of study        | Publication year | Non cancer Covid patients | Gynecology Oncology Covid patients | Other Oncology Covid patients | Cancer non Covid patients | Gender* | Cancer stage* | Comorbidities* | Cancer treatment* | Age* | Outcome          |
|------------------------|----------------|----------------------------|----------------------|------------------|--------------------------|-----------------------------------|-------------------------------|---------------------------|---------|---------------|----------------|------------------|------|-----------------|
| Dai M et al.           | China          | Multi center, prospective cohort | January–February 2020 | 2020             | 105                      | 8 (Cervical: 6, Ovarian: 1, Endometrial: 1) | 97 (Lung: 22, Breast: 11, Hematological: 8) | NA                         | Female: 46 | Male: 59       | Hypertension: 160, Cardiovascular disease: 51, Diabetes: 36, Cerebrovascular disease: 26, CKD: 28, Chronic liver disease: 42 | Surgery: 8, SACT: 27, Radiotherapy: 13 | <65: 54, >65: 51 | Covid death and Severe Covid |
| de Mello AC et al.     | Brazil         | Single center, retrospective cohort | April–May 2020       | 2020             | NA                       | 22 (Cervical: 12, Ovarian: 3, Endometrial: 5, Vulvar: 2) | 159 (Lung: 7, Breast: 40, Hematological: 34) | NA                         | Female: 110 | Male: 71       | Hypertension: 77, Diabetes: 31, CKD: 10, COPD/Asthma: 7 | Surgery: 12, Radiotherapy: 10, SACT: 88, Palliative: 32, Hormonal: 20 | <60: 89, 60–74: 67, >75: 25 | Covid death and Severe Covid |
| DeToro G et al.        | OOnCovid-Europe | Multi center, prospective cohort | February–June 2020   | 2021             | NA                       | 57                                | 1014 (Lung: 154, Breast: 177, Hematological: 87) | NA                         | Female: 231 | Male: 296      | Hypertension: 251, Diabetes: 115, Cardiovascular disease: 128, Chronic pulmonary disease: 80, CKD: 62, Cerebrovascular disease: 87, Liver impairment: 11, Immunosuppression: 16 | Ongoing treatment at diagnosis: 516, Surgery: 510, SACT: 319, Radiotherapy: 319, Palliative: 277 | Mean: 67.9 | Covid death |
| Duarte M et al.        | Brazil         | Multi center, prospective cohort | January–September 2020 | 2020             | 38468                    | 75 (Cervix: 47, Uterine: 6, Ovaries: 22) | 696 (Lung: 51, Breast: 90, Hematological: 155) | NA                         | Female: 374 | Male: 307       | Heart disease: 143, Diabetes: 104, Neurologic disease: 13, Chronic lung disease: 29, Nephropathy: 39 | SACT: 431 | <65: 441, >65: 240 | Covid death |
| Fang M et al.          | China          | Single center, retrospective cohort | February–April 2020  | pre-prints        | NA                       | 4                                | 52 (Lung: 9, Breast: 4, Hematological: 10) | NA                         | Female: 24 | Male: 32        | Hypertension: 23, Diabetes: 7, Cardiovascular disease: 5, Chronic pulmonary disease: 1, Cytosis: 2, CKD: 4 | NA | Median: 64, IQR: 54–71 | Covid death |
| Fernandes G et al.     | Brazil         | Cross sectional             | April–August 2020    | 2021             | NA                       | 26                                | 385 (Lung: 18, Breast: 93, Hematological: 47) | NA                         | Female: 234 | Male: 177       | NA                          | NA | <60: 215, >60: 196 | Covid death |
| Gladissy J et al.      | International  | Multi center, prospective cohort | April–June 2020      | 2020             | NA                       | 25                                | 263 (Lung: 25, Breast: 24, Other: 214) | 8683 (Gynecological: 1057) | Female: 119 | Male: 169       | Pre-existing respiratory condition: 45, Obese: 56 | Minor surgery: 36, Major surgery: 252 | <50: 30, 50–59: 39, 60–69: 87, 70–79: 96, >80: 36 | Covid infection |
| Grines P et al.        | CCC19-International | Multi center, prospective cohort | March–November 2020  | 2021             | NA                       | 322                               | 4796 (Lung: 409, Breast: 967, Hematological: 1097) | NA                         | Female: 2527 | Male: 2436      | Cardiovascular: 1582, Pulmonary: 1091, Renal disease: 831, Diabetes: 1385 | Chemotherapy: 802, Immunotherapy: 248, Targeted therapy: 693, Endocrine therapy: 483, Locoregional therapy: 422 | <65: 2282, 65–74: 1309, >75: 1375 | Covid hospitilization & Covid death |
| Hathout L et al.       | United States of America | Multi center, retrospective cohort | February–June 2020  | 2020             | NA                       | 3 (Cervical)                      | 0                                | 44 (Endometrial: 24, Cervical: 12) | Female: 3 | NA             | Respiratory disease: 1, Vascular disease: 23, Respiratory-Vascular: 4, HIV: 3 | Brachytherapy: 3 | NA | Covid infection |
| Author          | Location              | Type of study               | Time of study              | Non cancer Covid patients                   | Gynecology Oncology Covid patients | Other Oncology Covid patients | Cancer non Covid patients | Gender* | Cancer stage* | Comorbidities* | Cancer treatment* | Age* | Outcome                      |
|-----------------|-----------------------|-----------------------------|----------------------------|--------------------------------------------|----------------------------------|--------------------------------|----------------------------|---------|---------------|------------------|-------------------|-------|-----------------------------|
| Jee J et al.    | United States of America | Single center, retrospective cohort | March–April 2020          | NA                                         | 15 (Cervical 2, Endometrial 6, Ovarian 5, Vaginal 1, Vulvar 1) | 294 (Lung 29, Breast 56, Hematological 71) | NA                        | Female 150, Male 159 | Metastasis 168 | Pulmonary disease 35, Cardiовascular disease 221, Metabolic disease 156, Neurologic disease 29, HIV 3, Liver disease 4 | NA | Covid death and Severe Covid |
| Johannesen T et al. | Norway | Multi center, retrospective cohort | January–May 2020 | NA                                         | 33                                | 514 (Lung 13, Breast 85, Hematological 54) | NA                        | Localized 36, Distant disease 6 | NA | SACT 71, Surgery 90, Radiotherapy 7 | NA | Covid infection |
| Kulle C et al.  | Turkey                | Single center, retrospective cohort | March–June 2020           | NA                                         | 0                                | 1                           | NA                        | NA | NA | Surgery 1 | NA | Covid infection |
| Kuru B et al.   | Turkey                | Single center, retrospective cohort | March–October 2020        | 2                                         | 1 (Ovarian)                      | 0                           | Female 3                   | NA | Hypertension 2 | Surgery 1 | >65: 1 <65: 2 | Covid infection |
| Kovon D et al.  | United States of America | Multi center, retrospective cohort | February–December 2020    | NA                                         | 119                               | 1662 (Lung 33, Breast 241, Hematological 321) | NA                        | Female 950, Male 831 | NA | Heart disease 321, Pulmonary disease 294, CKD 273, Diabetes 474, Obese 481 | SACT 601, Hormonal therapy 86 | 18–65: 104, 65–75: 420, >75: 317 | Covid infection |
| Lara O et al.   | United States of America | Multi center, prospective cohort | March–June 2020           | NA                                         | 193 (Uterine 87, Epithelial Ovarian 62, Cervical 24, Vulva 8, Non-Epithelial Ovarian 3, Vaginal 3) | NA                        | NA                        | Female 193 | IIB: 74, IIIb: 100 | Hypertension 115, Diabetes 70, Asthma 21, COPD 5, Coronary artery disease 13, Autoimmune disease 18, CKD 21 | Surgery 12, Radiotherapy 8, SACT 98 | Median 65, IQR 54–73 | Covid hospitalization, Severe Covid & Covid death |
| Lee L et al.    | United Kingdom        | Multi center, retrospective cohort | March–April 2020          | NA                                         | 45                                | 755 (Lung 90, Breast 241, Hematological 321) | NA                        | Female 349, Male 449 | Localized 149, Metastatic 347, Advanced stage 78 | Cardiovascular disease 109, COPD 61, Diabetes 131, Hypertension 247 | SACT 461, Surgery 29, Radiotherapy 76 | Median 69, IQR 59–76 | Covid death |
| Lei S et al.    | China                 | Multi center, retrospective cohort | January–February 2020     | 25                                         | 1 (Ovarian)                       | 8                           | NA                        | Female 20, Male 14 | NA | Hypertension 13, Diabetes 8, Cardiovvascular disease 7, Cerebrovascular disease 2, COPD 1, CKD 1 | Surgery 9 | Median 55, IQR 43–63 | Covid death |
| Li H et al.     | United Kingdom        | Multi center, retrospective cohort | March–October 2020        | 275                                        | 17 (Uterine 7, Ovarian 10)         | 272 (Lung 18, Breast 102, Hematological 53) | 4161 (Uterine 107, Ovarian 115) | Female 120, Male 168 | NA | NA | 50–59: 28, 60–69: 62, 70–79: 159, 80–84: 39 | Covid infection & Covid death |
| Liang et al.    | China                 | Single center, retrospective cohort | January–April 2020        | NA                                         | 10 (Uterine 4, Cervical 5, Ovarian 1) | 99 (Lung 14, Breast 11, Hematological 12) | NA                        | Female 52, Male 57 | P/I: 86, N: 23 | Hypertension 38, Diabetes 18, Cardiovascular disease 10, Cerebrovascular disease 4, Chronic pulmonary disease 18, COPD 3, Chronic liver disease 10 | Surgery 69, Adjuvant 79, Chemo-radiation 71, Targeted Immuno-therapy 12 | >65: 55, <65: 54 | Covid death |
| Author                  | Country                  | Type of study          | Time of study | Other Oncology Covid patients | Carcinoma Non Covid patients | Gender Non Cancer Patients | Gender Cancer Patients | Other Oncology Covid patients | Carcinoma Covid patients | Gender | Other Oncology Covid patients | Cancer stage | Comorbidities* | Treatment* | Age* | Outcome |
|-------------------------|--------------------------|------------------------|---------------|--------------------------------|----------------------------|-----------------------------|-------------------------|-------------------------------|--------------------------|---------|---------------------------|------------------------|--------------------------|------------|-------|---------|
| Liu C et al.            | China                    | Multi center, prospective cohort | December 2019 - March 2020 | NA                               | NA                         | Female 103, Male 13         | NA                      | NA                            | NA                       | NA      | NA                         | I-II: 83, III-IV: 85 | Diabetes, Hypertension, Cardiovascular, Cerebrovascular, COPD, Chronic liver disease | Radiotherapy, Surgery | Median 63, IQR 57-70 | Covid death |
| Mehta V et al.          | United States of America | Single center, retrospective cohort | March - April 2020 | NA                               | 1090                        | Female 91, Male 127          | NA                      | NA                            | 12                       | 1090    | NA                         | Metastasis 42, Active cancer 92 | DM 80, Hypertension, Chronic lung disease, CKD, Coronary artery disease, CHF | Chemotherapy, Immunotherapy, Radiotherapy | Median 63, IQR 57-70 | Covid death |
| Modi C et al.           | United States of America | Multi center, prospective cohort | April-July 2020 | NA                               | NA                         | Female 3, Male 2             | NA                      | NA                            | 1                        | 331     | (Gynecologic) 20          | I-II: 3, III-IV: 2         | Female, Male | NA                      | Surgery 16 | NA      | NA      |
| Modi C et al.           | United States of America | Multi center, prospective cohort | May 2020 | NA                               | NA                         | Female 15, Male 18           | NA                      | NA                            | 1                        | 304     | (Gynecologic) 300         | Female, Male | NA      | NA      |
| Monroy-Iglesias M J et al. | Italy                  | Multi center, prospective cohort | March - September 2020 | NA                               | NA                         | Female 2                     | NA                      | NA                            | 2                        | 114     | (Gynecologic) 12          | Female 2 | NA      | NA      |
| Mousavi S et al.        | Iran                     | Single center, retrospective cohort | February - April 2020 | NA                               | NA                         | Female 15, Male 12           | NA                      | NA                            | 1                        | 5(Breast 1) | (Gynecologic) 7           | Female 2 | NA      | NA      |
| Nakamura S et al.       | Japan                    | Single center, prospective cohort | January - May 2020 | NA                               | NA                         | Female 15, Male 12           | NA                      | NA                            | 2                        | 31     | (Breast 1) | Female 2 | NA      | NA      |
| Ning M et al.           | China                    | Single center, prospective cohort | March - April 2020 | NA                               | NA                         | Female 15, Male 12           | NA                      | NA                            | 1                        | 115     | (Gynecologic) 12          | Female 2 | NA      | NA      |
| Roel E et al.           | Spain                    | Single center, retrospective cohort | March - May 2020 | NA                               | NA                         | Female 15, Male 12           | NA                      | NA                            | 13                       | NA     | (Gynecologic) 31           | Female 2 | NA      | NA      |

*Comorbidities: Diabetes, Hypertension, Cardiovascular, Cerebrovascular, COPD, Chronic liver disease, CKD, Coronary artery disease, CHF.
*Treatment: Chemotherapy, Immunotherapy, Radiotherapy.
*Age: Median, IQR.
*Outcome: Covid infection, Covid death.
| Author                     | Location     | Type of study                                      | Time of study                     | Non-Cancer patients | Gynecology Cancer patients | Other Oncology Cancer patients | Comorbidities* | Gender* | Cancer stage* | Other Information                          | Cancer Treatment* | Time of Covid infection | Outcome                  | COVID-19 death & Severe COVID-19 |
|---------------------------|--------------|---------------------------------------------------|-----------------------------------|---------------------|---------------------------|--------------------------------|----------------|---------|---------------|------------------------------------------|------------------|--------------------------|--------------------------|---------------------------|
| Russell B et al.          | United Kingdom | Single center, retrospective cohort                | March–June 2020                   | 10                  | Female 107, Male 112      | NA                             | NA             | Male    | I-II: 55, III-IV: 110 | NA                                      | SACT              | 92, Combination therapy          | Covid infection & Covid death |                           |
| Shi Z et al.              | United Kingdom | Multi center, prospective cohort                  | June 2020 pre-prints              | 86                  | Female 746, Male 816      | 409 (Lung 10, Breast 47, Hematological 49) | COPD 239, Asthma 1306, COPD 1306, Asthma 42, Heart Disease 120, Diabetes 232 | Female 746, Male 816 | Female | I-III: 2139, IV: 234 | NA                                      | Cancer: Mean 61.36, IQR 56.5–67.5, Non-cancer: Mean 56.11, IQR 47.5–64.5 |                           |
| Song C et al.             | China         | Multi center, retrospective cohort                 | December 2019–March 2020          | 51                  | Female 107, Male 116      | 206 (Lung 29, Breast 31, Ovarian 15) | NA             | Female 107, Male 116 | I-II: 55, III-IV: 110 | NA                                      | SACT              | 92, Combination therapy          | Covid infection & Covid death |                           |
| Song K et al.             | China         | Multi center, retrospective cohort                 | January–March 2020                 | 52                  | Female 120, Male 128      | 307 (Lung 24, Breast 40, Hematological 22) | COPD 239, Asthma 1306, COPD 1306, Asthma 42, Heart Disease 120, Diabetes 232 | Female 120, Male 128 | Female | I-III: 2139, IV: 234 | NA                                      | Cancer: Mean 61.36, IQR 56.5–67.5, Non-cancer: Mean 56.11, IQR 47.5–64.5 |                           |
| Tian J et al.             | China         | Multi center, retrospective cohort                 | January–March 2020                 | 53                  | Female 379, Male 372      | 217 (Lung 23, Breast 31, Ovarian 15) | NA             | Female 379, Male 372 | I-III: 192, IV: 34 | NA                                      | Surgery 25, Radiation therapy 10, Combined therapy 15, Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Villegas A et al.         | Spain         | Single center, retrospective cohort                | March–April 2020                   | 54                  | NA                         | 138                           | NA             | Female 2, Male 1   | NA | NA                                           | Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Wang Q et al.             | United America | Multi center, Case control cohort                  | August 2020                        | 55                  | NA                         | 140 (Lung 140, Hematological 220) | NA             | Male 1              | NA | NA                                           | Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Yang F et al.             | China         | Multi center, retrospective cohort                 | January–April 2020                 | 56                  | Female 24, Male 28        | 307 (Lung 24, Breast 60, Hematological 22) | COPD 239, Asthma 1306, COPD 1306, Asthma 42, Heart Disease 120, Diabetes 232 | Female 24, Male 28 | Female | I-III: 2139, IV: 234 | NA                                      | Cancer: Mean 61.36, IQR 56.5–67.5, Non-cancer: Mean 56.11, IQR 47.5–64.5 |                           |
| Yang G et al.             | China         | Multi center, retrospective cohort                 | January–March 2020                 | 57                  | Female 109, Male 96       | 142 (Lung 24, Breast 40, Hematological 22) | Hypertension 67, Diabetes 22,  Hypertension 67, Diabetes 22,  Hypertension 67, Diabetes 22,  Hypertension 67, Diabetes 22 | Female 109, Male 96 | Female | I-III: 2139, IV: 234 | NA                                      | Cancer: Mean 61.36, IQR 56.5–67.5, Non-cancer: Mean 56.11, IQR 47.5–64.5 |                           |
| Yang S et al.             | China         | Single center, retrospective cohort                | January–March 2020                 | 58                  | Female 1, Male 1          | 2 (Ovarian 1, Endometrial 1) | NA             | Male 1              | NA | NA                                           | Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Yang Y et al.             | China         | Multi center, retrospective cohort                 | January–March 2020                 | 59                  | Female 31                 | 6 (Ovarian 1, Endometrial 1, Ovarian 1) | NA             | Male 1              | NA | NA                                           | Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Yang Z et al.             | China         | Multi center, retrospective cohort                 | January–March 2020                 | 60                  | Female 3                  | 6 (Ovarian 1, Endometrial 1, Ovarian 1) | NA             | Male 1              | NA | NA                                           | Surgery 25, Radiation therapy 10, Combined therapy 15 |                           |
| Author          | Location | Type of study                  | Time of study      | Publication year | Non cancer Covid patients | Time of study | Type of study | Other Oncology Covid patients | Cancer non Covid patients | Gender* | Cancer stage* | Comorbidities* | Cancer treatment* | Age* | Outcome         |
|-----------------|----------|--------------------------------|--------------------|------------------|--------------------------|---------------|---------------|-----------------------------|--------------------------|-----------|---------------|----------------|----------------|---------|-----------------|
| Zhang L et al.  | China    | Multi-center, retrospective cohort | January-February 2020 | 2020             | NA                      | February 2020 | Multi-center, retrospective cohort | 59 (Ovary 1, Endometrial 1, Cervix 1) | 25 (Lung 7, Breast 3) | NA        | Female 11, Male 17 | Diabetes 4, Cardiovascular disease 4, Chronic pulmonary disease 1, Chronic liver disease 2 | Surgery 21, Chemotherapy 25, Targeted Therapy 6 | Median 65, IQR 66–70 | Covid death and Severe Covid |
| Zhou K et al.   | France   | Multi-center, retrospective cohort | June-November 2020  | 2021             | NA                      | March 2021    | Multi-center, retrospective cohort | 65 (Lung 8, Breast 36) | 808 (Gynecological 81)  | Female 56, Male 14 | Localized 19, Locally advanced 9, Metastasis 32 | Hypertension 18, Diabetes 6, COPD 3, Heart failure 2, Autoimmune disease 2 | SACT 70, Radiotherapy 2, Surgery 4 | Median 61, IQR 27–81 | Covid infection |

*CCC19: the clinical impact of Covid-19 patients with cancer study, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, NA: not addressed, SACT: systemic anti-cancer therapy.
*Covid-19 population.
*Charlson comorbidity index.
Gynecologic cancer VS other cancer

Covid-19 infection was equivalent between gynecologic cancer and other cancer patients gathered from eight studies (OR 1.02, CI 0.84–1.22, p = 0.87, I^2 57%) Figure S3. Gynecologic cancer patients had fewer Covid-19 associated deaths compared to other cancers according to 30 studies (OR 0.82, CI 0.71–0.94, p = 0.006, I^2 0%) Figure 2. Covid-19 associated severity was not significant from six studies between gynecologic cancer and other cancer types (OR 0.56, CI 0.30–1.03, p = 0.06, I^2 0%) Figure S4. Data from two studies also showed no significant difference in Covid-19 hospitalizations between gynecologic cancer patients than other cancers (OR 0.73, CI 0.50–1.06, p = 0.10, I^2 82%) Figure S5.

Gynecologic cancer VS non-cancer

Covid-19 infection among gynecologic cancer patients and the non-cancer population was not significant from six studies (OR 1.55, CI 0.81–2.95, p = 0.18, I^2 90%) Figure S6. Data from 11 studies revealed death from Covid-19 was higher in gynecologic cancer than non-cancer patients (OR 2.98, CI 2.23–3.98, p < 0.0001, I^2 30%) Figure 3. However, severe Covid-19 cases showed no significant difference between gynecologic cancer than non-cancer patients from two studies (OR 1.85, CI 0.77–4.44, p = 0.17, I^2 0%) Figure S7.

Gynecologic cancer VS non-covid

Data represented from five studies revealed that gynecologic cancer patients were experiencing higher Covid-19 associated death in comparison to other cancer patients without Covid-19 infection (OR 11.83, CI 8.20–17.07, p < 0.0001, I^2 5%) Figure 4.

Cancer treatment group

We analyzed the effect of active cancer treatment comprising SACT (systemic anti-cancer therapy), radiotherapy, cancer surgery, and hormonal therapy. Data from nine studies showed that, among those who receive active cancer treatment, Covid-19 infection was not significant in gynecologic cancer patients compared to other cancer types (OR 0.75, CI 0.55–1.02, p = 0.07, I^2 0%) Figure S8. Covid-19 death was not significant among cancer treatment between gynecologic cancer and other cancer types gathered from nine studies (OR 0.86, CI 0.41–1.78, p = 0.68, I^2 0%) Figure S9. Severe Covid-19 cases among those who were receiving active cancer treatment showed no significant difference between gynecologic cancer than other cancer according to six studies (OR 0.63, CI 0.18–2.25,

![Figure 2. Gynecologic cancer VS other cancer, Covid-19 death. M-H: mantel-haenszel, CI: confidence interval.](image-url)
According to five studies, Covid-19 associated death was comparable in gynecologic cancer with active cancer treatment compared to those who were not receiving cancer treatment (OR 1.06, CI 0.57–1.98, \( p = 0.86, I^2 = 0\%\)).

Lastly, five studies showed severity from Covid-19 was not significant in gynecologic cancer patients who had active cancer treatment compared to those who had none (OR 0.45, CI 0.17–1.20, \( p = 0.11, I^2 = 26\%)\).

There were two studies available for cancer stage analysis.\(^{23,24}\) Overall, adverse Covid-19 events (infection/hospitalization/severity/death) showed no significance between stage I-II gynecologic cancer against stage III-IV other cancer, stage III-IV gynecologic cancer against stage I-II other cancer, and among all cancer patients who had stage III-IV cancer (OR 0.78, CI 0.04–16.18, \( p = 0.88, I^2 = 0\%\)), (OR 0.48, CI 0.15–1.53, \( p = 0.21, I^2 = 0\%\)), (OR 0.59, CI 0.22–1.58, \( p = 0.29, I^2 = 0\%\)) respectively\(^{23,24,31,35}\). No significance on Covid-19 adverse events between stage III-IV and I-II gynecologic cancer was found in three studies (OR 0.72, CI 0.39–1.33, \( p = 0.29, I^2 = 0\%\)).

There were three studies that provided data on metastatic status.\(^{19,24,38}\) Gynecologic cancer with metastasis had increased Covid-19 associated death than those with localized cancer (OR 1.53, CI 1.06–2.21, \( p = 0.02, I^2 = 0\%\)).

Cancer stage and metastatic cancer

There were two studies available for cancer stage analysis.\(^{23,24}\) Overall, adverse Covid-19 events (infection/hospitalization/severity/death) showed no significance between stage I-II gynecologic cancer against stage III-IV other cancer, stage III-IV gynecologic cancer against stage I-II other cancer, and among all cancer patients who had stage III-IV cancer (OR 0.78, CI 0.04–16.18, \( p = 0.88, I^2 = 0\%\)), (OR 0.48, CI 0.15–1.53, \( p = 0.21, I^2 = 0\%\)), (OR 0.59, CI 0.22–1.58, \( p = 0.29, I^2 = 0\%\)) respectively\(^{23,24,31,35}\). No significance on Covid-19 adverse events between stage III-IV and I-II gynecologic cancer was found in three studies (OR 0.72, CI 0.39–1.33, \( p = 0.29, I^2 = 0\%\)).

There were three studies that provided data on metastatic status.\(^{19,24,38}\) Gynecologic cancer with metastasis had increased Covid-19 associated death than those with localized cancer (OR 1.53, CI 1.06–2.21, \( p = 0.02, I^2 = 0\%\)).
among those who had metastatic diseases, Covid-19 death was not significant between gynecologic cancer compared to other cancer types (OR 0.77, CI 0.54–1.11, p 0.17, I² 0%) Figure S17.

**Gynecologic cancer vs lung cancer**

A total of 13 studies provided data on Covid-19 infectivity, infection was not significant in gynecologic cancer than lung cancer (OR 0.86, CI 0.61–1.20, p 0.37, I² 73%) Figure S18.14,16,22,28,32,38,42,49,50,55,60 Data from 30 studies revealed that gynecologic cancer had fewer Covid-19 deaths than lung cancer patients (OR 0.52, CI 0.44–0.62, p < 0.0001, I² 0%) Figure 6A.14,17–20,23–27,29,31,36,38,39–41,44,45,47–49,51–53,56,57 Data from six studies showed that gynecologic cancer was having less severity from Covid-19 than lung cancer (OR 0.36, CI 0.16–0.80, p 0.01, I² 0%) Figure 6B.23,24,31,52,53,59 Lastly, two studies reported fewer hospitalizations associated with Covid-19 in gynecologic cancer than lung cancer (OR 0.54, CI 0.40–0.73, p < 0.0001, I² 0%) Figure 6C.16,20

---

**Figure 6.** Gynecologic cancer vs lung cancer, (A) Covid-19 death, (B) Severe Covid-19, (C) Covid-19 hospitalization. M-H; mantel-haenszel, CI; confidence interval.
Gynecologic cancer VS breast cancer

Data from 13 studies showed gynecologic cancer and breast cancer were equivalent on the rate of Covid-19 infection (OR 1.05, CI 0.94–1.17, p = 0.37, $I^2$ 7%) Figure S19. Interestingly, from 25 studies, gynecologic cancer patients experience higher Covid-19 death compared to breast cancer patients (OR 1.50, CI 1.20–1.88, p = 0.0004, $I^2$ 19%) Figure 7A. Covid-19 severity was not significant from seven studies between gynecologic cancer and breast cancer patients (OR 0.83, CI 0.40–1.72, p = 0.62, $I^2$ 0%) Figure S20. Lastly, data from two studies showed gynecologic cancer patients experience higher hospitalization from Covid-19 compared to breast cancer (OR 1.52, CI 1.18–1.96, p = 0.001, $I^2$ 0%) Figure 7B.

Gynecologic cancer VS hematologic cancer

Data available from eight studies revealed gynecologic cancer patients had less Covid-19 infections compared to hematologic cancer patients (OR 0.71, CI 0.56–0.90, p = 0.005, $I^2$ 68%) Figure 8A. Data also showed that gynecologic cancer patients were experiencing fewer Covid-19 deaths compared to hematologic cancer from 24 studies (OR 0.63, CI 0.47–0.83, p = 0.001, $I^2$ 46%) Figure 8B. Lastly, four studies also showed that gynecologic cancer patients were having less severity from Covid-19 compared to hematologic cancer (OR 0.26, CI 0.10–0.67, p = 0.005, $I^2$ 0%) Figure 8C.

Gynecologic cancer VS men

Based on 10 studies available for synthesis, there was no significance on Covid-19 infection between gynecologic cancer population and men with cancer (OR 0.58, CI 0.27–1.22, p = 0.15, $I^2$ 94%) Figure S21. Compared to men with cancer, the Covid-19 associated death retrieved from 23 studies showed no significant difference (OR 0.75, CI 0.54–1.05, p = 0.09, $I^2$ 23%) Figure S22. According to six studies, severe Covid-19 was higher in men with cancer compared to gynecologic cancer patients (OR 0.47, CI 0.25–0.88, p = 0.02, $I^2$ 0%)

---

**Figure 7.** Gynecologic cancer VS breast cancer, (A) Covid-19 death, (B) Covid-19 hospitalization. M-H; mantel-haenszel, CI; confidence interval.
Hospitalization from Covid-19 was also higher in men with cancer compared to gynecologic cancer patients synthesized from two studies (OR 0.71, CI 0.56–0.89, p 0.004, I² 0%) Figure 9A. 

Data from four studies showed that among the gynecologic cancer population, those who were >65 compared to <65 years of age had comparable overall adverse Covid-19 outcomes (infection/hospitalization/severity/death), (OR 1.13, CI 0.48–2.62, p 0.78, I² 14%) Figure S2A. We performed a pairwise comparison of gynecologic cancer with <65 year old gynecologic cancer patients against other cancer with >65 years old, and gynecologic cancer with >65 years old against other cancer with <65 years old. Covid-19 adverse outcome was found to be lower in <65 year old gynecologic cancer than >65 years old other cancer population (OR 0.16, CI 0.06–0.47, p 0.0007, I² 0%) Figure 10. Contrary, there...
was an equivalent Covid-19 adverse outcome between gynecologic cancer with >65 years old and other cancer with <65 years old (OR 1.08, CI 0.36–3.26, p = 0.89, I² 0%) Figure S24.

Comorbidities
Cancer is a comorbidity, aside from which we tried to analyze other comorbidities (hypertension, diabetes, cardiovascular disease, pulmonary disease, renal disease, liver disease, immune disease, metabolic-endocrine disease) present within the cancer population. Among those with comorbidities, gynecologic cancer patients had fewer adverse Covid-19 outcomes than other cancer populations according to four studies (OR 0.31, CI 0.06–0.82, p = 0.02, I² 0%) Figure 11.20,23,24,59 Data from five studies showed there was no significant adverse Covid-19 outcome between gynecologic cancer patients with comorbidities against no comorbidities (OR 2.34, CI 0.59–9.79, p = 0.24, I² 79%) Figure S25.15,21,23,24,35 Gynecologic cancer patients without comorbidities against other cancer patients with comorbidities had no significant difference in
adverse Covid-19 outcomes, according to three studies (OR 0.29, CI 0.04–2.22, p 0.23, I² 56%) Figure S26. 23,24,59
Gynecologic cancer patients with comorbidities against other cancer patients without comorbidities also showed no
significant difference in adverse Covid-19 outcomes, according to four studies (OR 0.61, CI 0.22–1.72, p 0.35, I² 0%) Figure S27. 50,23,24,59

Sensitivity analysis
We performed sensitivity analysis by reproducing each outcome synthesis to pre-specified single center to multi-center
studies, furthermore excluding overlapped study periods associated with its study centers, thus only one center with the
most recent study period was included in Table S1. After exclusion of three studies, a difference of significance was
found in severe Covid-19 between gynecologic cancer and cancer men population (OR 0.47, CI 0.19–1.17, p 0.10,
I² 0%)52,31,52 Aside from that, the remainder of the calculated OR from reproducing each outcome synthesis by exclusion
were within good accordance.

Publication bias
We found no publication bias within our included studies though at first, we identified an asymmetrical funnel plot; it was
caused solely by heterogeneity nonetheless (Figures S28–31). After subgroup identification, the funnel plot was
corrected and the calculated Egger & Begg’s test for overall Covid death, severity, and hospitalization were p 0.15
and p 1.6. For data associated with Covid-19 infection, the values were p 0.17 and p 1.87.

Discussion
We believe this is the first comprehensive meta-analysis with a large population regarding the outcome of Covid-19 on
the gynecologic cancer population. With the 1991 Covid-19 positive gynecologic cancer, we hope we provide new
insight into how the global pandemic is affecting practice and services affecting gynecologic cancer. Several meta-
analyses showed the prevalence of cancer with Covid-19 infection was 2–4%, Covid-19 mortality was also higher in the
cancer patients cohort. 52–54,61–65 In this meta-analysis, it was found that gynecologic cancer patients are at an increased risk
of Covid-19 death compared to the non-cancer population (OR 2.98, CI 2.23–3.98, p < 0.0001, I² 50%), most studies also support this finding by providing evidence of greater Covid-19 adverse outcome in cancer patients.5

Further analysis shows that gynecologic cancer patients with Covid-19 have fewer adverse outcome compared to Covid-
19 lung and hematologic cancer. Our findings are (OR 0.52, CI 0.44
–17.07, p < 0.0001, I² 5%).66 Our finding shows gynecologic cancer with metastatic disease has an increased Covid-19
death compared to those whose cancer is localized (OR 1.53, CI 1.06–2.21, p 0.02, I² 0%), most studies also report
identical outcomes to ours.65,67,68 Our analysis also shows gynecologic cancer is associated with higher Covid-19 death
and hospitalization compared to breast cancer patients (OR 1.50, CI 1.20–1.88, p 0.0004, I² 19%), (OR 1.52, CI 1.18–
1.96, p 0.001, I² 0%) respectively. Other meta-analyses, as well as studies done by the clinical impact of Covid-19 patients
with cancer (CCC19) and the “N3C” also supported this finding.52,66,67 Our analysis presents that gynecologic cancer
patients have lower Covid-19 death compared to overall other cancer types (OR 0.82, CI 0.71–0.94, p 0.006, I² 0%).
Further analysis shows that gynecologic cancer patients with Covid-19 have fewer adverse outcome compared to Covid-
19 lung and hematologic cancer. Our findings are (OR 0.52, CI 0.44–0.62, p < 0.0001, I² 0%), (OR 0.36, CI 0.16–0.80,
p 0.01, I² 0%), (OR 0.54, CI 0.40–0.73, p < 0.0001, I² 0%) for Covid-19 associated death, severity, and hospitalization
versus lung cancer respectively. Hematologic cancer (OR 0.71, CI 0.56–0.90, p 0.005, I² 68%), (OR 0.63, CI 0.47–0.83,
p 0.001, I² 46%), (OR 0.26, CI 0.10–0.67, p 0.005, I² 0%) for Covid-19 infectivity, death, and severity respectively. The
“TERAVOLT” study and the one conducted by Luo et al. also support our finding of a high level of Covid-19 associated
adverse outcomes among lung cancer patients.69,70 Other meta-analyses show lung cancer with Covid-19 has a 32.9%
case fatality rate (378 lung cancer), compared to the non-lung cancer population the Covid-19 death among lung cancer
is also higher (92 lung cancer, 554 control, OR 1.83, p 0.05), (78 lung cancer, 482 control, RR 1.46, p 0.7),5,62,63 Lastly,
most studies also support our findings on the increased Covid-19 adverse outcome in the hematologic cancer population,
as their results are 34.2% case fatality rate (480 hematologic cancer), (120 hematologic cancer, 758 control, OR 2.39,
p 0.02).62,63,65–68 We believe our meta-analysis results correspond to several studies that present the safety of continuing
gynecologic cancer care and service during the global pandemic. Safety protocols have been published for gynecologic
cancer patients who are seeking treatment and some even recommend the implementation of ERAS (Enhanced Recovery
After Surgery).71,72 Data from the French Society for Pelvic and Gynecological Surgery (SCGP) and the French
(FRANCOCYGN) Group reveal there are changes in cancer management strategy during the pandemic time and from
181 gynecologic cancer patients, eight tested positive for Covid-19.73 A multicenter study from three New York City
hospitals also show a similar result; among 302 gynecologic cancer patients, 117 experienced a COVID-19-related
treatment modification, 19 had a positive Covid-19 result and among them three were asymptomatic, 11 had mild
symptoms, three were hospitalized, and two died.74 Lastly, data from the United Kingdom, Turkey, and Italy show that
while maintaining gynecologic cancer treatment during the pandemic time the Covid-19 infection rate is found at a
low level, 1/289 is Covid-19 positive and 1 post-operative death suspected of Covid-19 (UK), 2/200 is suspected with
Covid-19 but neither was positive for COVID-19 on polymerase chain reaction testing (Turkey), and 1/930 is Covid-19 positive (Italy).\textsuperscript{75–77} Other meta-analysis shows Covid-19 infection with existing comorbidities such as hypertension (OR 1.95, \( p < 0.0001 \)), diabetes (OR 1.97, \( p < 0.0001 \)), respiratory disease (OR 2.74, \( p < 0.0001 \)), cardiovascular disease (OR 3.05, \( p < 0.0001 \)), cerebrovascular disease (OR 4.78, \( p < 0.0001 \)), kidney disease (OR 4.90, \( p < 0.0001 \)), and cancer (OR 1.89, \( p < 0.0001 \)) increase the risk of mortality.\textsuperscript{78} Our analyzed population comprises cancer as the main comorbidity, however with comorbidities other than cancer, our study shows that the gynecologic cancer population with additional comorbidities has fewer adverse events than other cancer with comorbidities (OR 0.31, CI 0.12–0.82, \( p = 0.02, I^2 = 0\% \)). Other meta-analyses prove that men have increased Covid-19 severity and mortality.\textsuperscript{78,79} Our findings correspond by showing that severity and hospitalization from Covid-19 were higher in men with cancer compared to gynecologic cancer patients (OR 0.47, CI 0.25–0.88, \( p = 0.02, I^2 = 0\% \)), (OR 0.71, CI 0.56–0.89, \( p = 0.004, I^2 = 0\% \)) respectively. Age thresholds above 50 and 60 years old have an effect on Covid-19 mortality.\textsuperscript{78,80} In our study Covid-19 adverse outcome was lower in <65 years old gynecologic cancer than <65 years old other cancer patients (OR 0.16, CI 0.06–0.47, \( p = 0.0007, I^2 = 0\% \)). Other meta-analysis on Covid-19 with active cancer treatment shows that cancer surgery (OR 1.14, \( p < 0.01 \)), chemotherapy (OR 1.60, \( p < 0.01 \)), and overall cancer treatment type (OR 1.16, \( p = 0.004, I^2 = 0\% \)) have a higher risk of death.\textsuperscript{81} However in our study Covid-19 death is equivalent in gynecologic cancer with active cancer treatment compared to those who are not receiving cancer treatment (OR 1.06, CI 0.57–1.98, \( p = 0.86, I^2 = 0\% \)).

We hope these findings will be useful among gynecologist-oncologists in cancer centers or tertiary cancer referral centers who provide care to gynecologic cancer patients during the ongoing Covid-19 pandemic.

In several data syntheses with the statistically nonsignificant value, we analyze few data regarding severity, hospitalization, age, cancer stage/metastatic status, other comorbidities aside from cancer, and cancer treatment type due to limited data, however those aforementioned are well represented and distributed through other synthesis based on the patient’s characteristics available in Table 1.

**Data availability**

**Underlying data**

Figshare: Systematic review and Meta-analysis file. https://doi.org/10.6084/m9.figshare.19470131.\textsuperscript{82}

This project contains the following underlying data:

- Outcome of Gynaecologic Cancer Patients With The Covid-19 Infection A Systematic Review And Meta Analysis (26.3.2022).rm5
- Meta Quilitative.xlsx
- Meta Data.xlsx
- Table 1.docx

**Extended data**

This project contains the following extended data:

- Supplementary Materials.docx

**Reporting guidelines**

Figshare: PRISMA checklist and flow diagram for ‘The outcome of gynecologic cancer patients with Covid-19 infection: A systematic review and meta-analysis’. https://doi.org/10.6084/m9.figshare.19470131.\textsuperscript{82}

Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).

**Acknowledgments**

We thank the staff of Gynecology Oncology (Sanglah Hospital, Faculty of Medicine, Udayana University, Denpasar, Bali, Indonesia), staff of Reproductive Endocrinology and Infertility (Morula IVF), (School of Medicine and Health Sciences, Atmajaya Catholic University of Indonesia, Jakarta, Indonesia), and staff of Department of Obstetrics and Gynecology (UKI Hospital, Faculty of Medicine, Christian University of Indonesia, Jakarta, Indonesia) to make this research collaboration possible.
71. Thomakos N, Pandraklakis A, Bisch SP, et al.: ERAS protocols in gynecologic oncology during COVID-19 pandemic. Int J Gynecol Cancer. 2020; 30(6): ijgc-2020-001439.

Publisher Full Text

72. Bisch SP, Jago CA, Kalogera E, et al.: Outcomes of enhanced recovery after surgery (ERAS) in gynecologic oncology – A systematic review and meta-analysis. Gynecol Oncol. 2021; 161(1): 46–55.

PubMed Abstract | Publisher Full Text

73. Jouen T, Gauthier T, Azais H, et al.: The impact of the COVID-19 coronavirus pandemic on the surgical management of gynecological cancers: Analysis of the multicenter database of the French SGCP and the FRANCOGYN group. J Gynecol Obstet Hum Reprod. 2021; 50(8): 102133.

PubMed Abstract | Publisher Full Text

74. Frey MK, Fowlkes RK, Badiner NM, et al.: Gynecologic oncology care during the COVID-19 pandemic at three affiliated New York City hospitals. Gynecol Oncol. 2020; 159(2): 470–475.

PubMed Abstract | Publisher Full Text

75. Leung E, Peraza Z, Lowe-Zinola J, et al.: Maintaining surgical care delivery during the COVID-19 pandemic: A comparative cohort study at a tertiary gynecological cancer centre. Gynecol Oncol. 2021; 160(3): 640–644.

PubMed Abstract | Publisher Full Text

76. Dursun P, Derisoglu H, Daggez M, et al.: Performing gynecologic cancer surgery during the COVID-19 pandemic in Turkey: A multicenter retrospective obser.

77. Palluzzi E, Corrado G, Marchetti C, et al.: Medical treatment of patients with gynecologic cancer during the COVID-19 pandemic. Int J Gynecol Cancer. 2021; 31(8): 1154–1158.

Publisher Full Text

78. Biswas M, Rahaman S, Biswas T, et al.: Association of Sex, Age, and Comorbidities with Mortality in COVID-19 Patients: A Systematic Review and Meta-Analysis. Intervirology. 2021; 64: 36–47.

PubMed Abstract | Publisher Full Text

79. Peckham H, de Gruijter NM, Raine C, et al.: Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020; 11: 6317.

PubMed Abstract | Publisher Full Text

80. Bonanad C, Garcia-Blas S, Tarazona-Santabalbina F, et al.: The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. J Am Med Dir Assoc. 2020; 21(7): 915–918.

Publisher Full Text

81. Park R, Lee SA, Kim SY, et al.: Association of active oncologic treatment and risk of death in cancer patients with COVID-19: a systematic review and meta-analysis of patient data. Acta Oncol (Madrid). 2021; 60(1): 13–19.

PubMed Abstract | Publisher Full Text

82. Winata IGS, Simatupang J, Polim AA, et al.: One-Year and Consequences of COVID-19 in Cancer Patients: a Cohort Study. 18 May 2021; PREPRINT (Version 1) available at Research Square.

Publisher Full Text

83. Chai C, Feng X, Lu M, et al.: Clinical characteristics, outcomes and follow-up of COVID-19 infection in cancer patients. 08 June 2020; PREPRINT (Version 1) available at Research Square.

Publisher Full Text

84. Fang M, Ling J, Wu Y, et al.: Association of Cancer with Risk and Mortality of COVID-19: Results from the UK Biobank. medRxiv. Published online January 1, 2020: 2020.07.10.20151076.

Publisher Full Text
The benefits of publishing with F1000Research:

• Your article is published within days, with no editorial bias
• You can publish traditional articles, null/negative results, case reports, data notes and more
• The peer review process is transparent and collaborative
• Your article is indexed in PubMed after passing peer review
• Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com